{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:16:01Z","timestamp":1795025761855,"version":"4.10.2"},"reference-count":60,"publisher":"American Association for Cancer Research (AACR)","issue":"10","funder":[{"DOI":"10.13039\/501100013904","name":"Swiss Bridge Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003975","name":"Israel Cancer Association","doi-asserted-by":"publisher","award":["20180041"],"award-info":[{"award-number":["20180041"]}],"id":[{"id":"10.13039\/501100003975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2262\/18"],"award-info":[{"award-number":["2262\/18"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The recent success of checkpoint blockade therapies has established immunotherapy as one of the most promising treatments for melanoma. Nonetheless, a complete curative response following immunotherapy is observed only in a fraction of patients. To identify what factors limit the efficacy of immunotherapies, we established mouse models that cease to respond to immunotherapies once their tumors exceed a certain stage. Analysis of the immune systems of the organisms revealed that the numbers of tumor-infiltrating dendritic cells (TIDC) drastically decreased with time. Further, in contrast to the current paradigm, once melanoma was established, TIDC did not migrate into sentinel lymph nodes. Instead, they underwent local cell death due to excessive phagocytosis of lysosomes. Importantly, TIDC were required to license the cytotoxic activity of tumor CD8+ T cells, and in their absence, T cells did not lyse melanoma cells. Our results offer a paradigm shift regarding the role of TIDC and a framework to increase the efficacy of immunotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This work redefines the role of monocyte-derived dendritic cells in melanoma and provides a novel strategy to increase the efficacy of T-cell\u2013based immunotherapies in nonresponding individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-19-2944","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T15:34:20Z","timestamp":1583249660000},"page":"1942-1956","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy"],"prefix":"10.1158","volume":"80","author":[{"given":"Nadine","family":"Santana-Magal","sequence":"first","affiliation":[{"name":"1Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Farhat-Younis","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Gutwillig","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Gleiberman","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rasoulouniriana","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Tal","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvir","family":"Netanely","sequence":"additional","affiliation":[{"name":"2Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Shamir","sequence":"additional","affiliation":[{"name":"2Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-8894","authenticated-orcid":false,"given":"Rachel","family":"Blau","sequence":"additional","affiliation":[{"name":"3Department of Physiology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meora","family":"Feinmesser","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."},{"name":"4Institute of Pathology, Rabin Medical Center \u2013 Beilinson Hospital, Petach Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9965-9432","authenticated-orcid":false,"given":"Oran","family":"Zlotnik","sequence":"additional","affiliation":[{"name":"5Department of Surgical Oncology Unit, Rabin Medical Center-Beilinson Campus, Petach Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Gutman","sequence":"additional","affiliation":[{"name":"5Department of Surgical Oncology Unit, Rabin Medical Center-Beilinson Campus, Petach Tikva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian L.","family":"Linde","sequence":"additional","affiliation":[{"name":"6School of Medicine, Department of Pathology, Stanford University, Palo Alto, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan E.","family":"Reticker-Flynn","sequence":"additional","affiliation":[{"name":"6School of Medicine, Department of Pathology, Stanford University, Palo Alto, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peleg","family":"Rider","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Carmi","sequence":"additional","affiliation":[{"name":"1Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"2022061706321030700_bib1","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1200\/JCO.2012.47.3728","article-title":"Melanoma epidemic: an analysis of six decades of data from the Connecticut Tumor Registry","volume":"31","author":"Geller","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022061706321030700_bib2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/onc.2009.416","article-title":"Immune infiltration in human tumors: a prognostic factor that should not be ignored","volume":"29","author":"Pages","year":"2010","journal-title":"Oncogene"},{"key":"2022061706321030700_bib3","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"2022061706321030700_bib4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrclinonc.2014.174","article-title":"Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment","volume":"11","author":"Rosenberg","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706321030700_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"2022061706321030700_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2022061706321030700_bib7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2022061706321030700_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"2022061706321030700_bib9","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022061706321030700_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"2022061706321030700_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"2022061706321030700_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"2022061706321030700_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"2022061706321030700_bib14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"2022061706321030700_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"2022061706321030700_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.immuni.2014.04.016","article-title":"Development and function of dendritic cell subsets","volume":"40","author":"Mildner","year":"2014","journal-title":"Immunity"},{"key":"2022061706321030700_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2022061706321030700_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2022061706321030700_bib19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"2022061706321030700_bib20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"2022061706321030700_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"2022061706321030700_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"2022061706321030700_bib23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fimmu.2013.00454","article-title":"Dendritic cells in cancer immunotherapy clinical trials: are we making progress","volume":"4","author":"Butterfield","year":"2013","journal-title":"Front Immunol"},{"key":"2022061706321030700_bib24","doi-asserted-by":"crossref","first-page":"e89020","DOI":"10.1172\/jci.insight.89020","article-title":"Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity","volume":"1","author":"Carmi","year":"2016","journal-title":"JCI Insight"},{"key":"2022061706321030700_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature14424","article-title":"Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity","volume":"521","author":"Carmi","year":"2015","journal-title":"Nature"},{"key":"2022061706321030700_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.188.2.277","article-title":"gp100\/pmel 17 is a murine tumor rejection antigen: induction of \"self\"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand","volume":"188","author":"Overwijk","year":"1998","journal-title":"J Exp Med"},{"key":"2022061706321030700_bib27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1186\/s12885-016-2982-x","article-title":"Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model","volume":"16","author":"Caisova","year":"2016","journal-title":"BMC Cancer"},{"key":"2022061706321030700_bib28","doi-asserted-by":"crossref","first-page":"283ra52","DOI":"10.1126\/scitranslmed.aaa4306","article-title":"STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade","volume":"7","author":"Fu","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022061706321030700_bib29","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706321030700_bib30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2015.03.004","article-title":"Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2","volume":"27","author":"Zhu","year":"2015","journal-title":"Cancer Cell"},{"key":"2022061706321030700_bib31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/jre.12641","article-title":"Myd88 plays a major role in the keratinocyte response to infection with Porphyromonas gingivalis","volume":"54","author":"Polak","year":"2019","journal-title":"J Periodontal Res"},{"key":"2022061706321030700_bib32","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1172\/JCI127590","article-title":"A distinct subset of FcgammaRI-expressing Th1 cells exert antibody-mediated cytotoxic activity","volume":"129","author":"Rasoulouniriana","year":"2019","journal-title":"J Clin Invest"},{"key":"2022061706321030700_bib33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"2022061706321030700_bib34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"2022061706321030700_bib35","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res"},{"key":"2022061706321030700_bib36","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/pcmr.12498","article-title":"The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations","volume":"29","author":"Meeth","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"2022061706321030700_bib37","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas N","year":"2015","journal-title":"Cell"},{"key":"2022061706321030700_bib38","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat Med"},{"key":"2022061706321030700_bib39","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2022061706321030700_bib40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"2022061706321030700_bib41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"2022061706321030700_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"2022061706321030700_bib43","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/1097-0142(20010601)91:11<2136::AID-CNCR1242>3.0.CO;2-Q","article-title":"The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma","volume":"91","author":"Reichert","year":"2001","journal-title":"Cancer"},{"key":"2022061706321030700_bib44","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00262-007-0286-3","article-title":"Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor","volume":"56","author":"Ladanyi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"2022061706321030700_bib45","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res"},{"key":"2022061706321030700_bib46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/1523-1747.ep12464142","article-title":"Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin","volume":"91","author":"Stene","year":"1988","journal-title":"J Invest Dermatol"},{"key":"2022061706321030700_bib47","doi-asserted-by":"crossref","first-page":"269S","DOI":"10.1038\/jid.1993.48","article-title":"Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin","volume":"100","author":"Toriyama","year":"1993","journal-title":"J Invest Dermatol"},{"key":"2022061706321030700_bib48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jlb.66.2.336","article-title":"Tumor's other immune targets: dendritic cells","volume":"66","author":"Esche","year":"1999","journal-title":"J Leukoc Biol"},{"key":"2022061706321030700_bib49","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.4049\/jimmunol.170.7.3488","article-title":"Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis","volume":"170","author":"Peguet-Navarro","year":"2003","journal-title":"J Immunol"},{"key":"2022061706321030700_bib50","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/glycob\/cwp015","article-title":"Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells","volume":"19","author":"Bennaceur","year":"2009","journal-title":"Glycobiology"},{"key":"2022061706321030700_bib51","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/pmic.200800039","article-title":"Mucin-induced apoptosis of monocyte-derived dendritic cells during maturation","volume":"8","author":"Ishida","year":"2008","journal-title":"Proteomics"},{"key":"2022061706321030700_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"2022061706321030700_bib53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"2022061706321030700_bib54","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.4049\/jimmunol.1301135","article-title":"Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents","volume":"191","author":"Kuhn","year":"2013","journal-title":"J Immunol"},{"key":"2022061706321030700_bib55","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"2022061706321030700_bib56","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1074-7613(00)80149-1","article-title":"Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo","volume":"11","author":"Randolph","year":"1999","journal-title":"Immunity"},{"key":"2022061706321030700_bib57","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022061706321030700_bib58","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fimmu.2014.00165","article-title":"Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets","volume":"5","author":"Wimmers","year":"2014","journal-title":"Front Immunol"},{"key":"2022061706321030700_bib59","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.4049\/jimmunol.166.6.4254","article-title":"Dendritic cells injected via different routes induce immunity in cancer patients","volume":"166","author":"Fong","year":"2001","journal-title":"J Immunol"},{"key":"2022061706321030700_bib60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ccell.2016.08.004","article-title":"T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells","volume":"30","author":"Marigo","year":"2016","journal-title":"Cancer Cell"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/10\/1942\/2791313\/1942.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/10\/1942\/2791313\/1942.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T15:23:14Z","timestamp":1655479394000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/80\/10\/1942\/640907\/Melanoma-Secreted-Lysosomes-Trigger-Monocyte"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,5,15]]},"published-print":{"date-parts":[[2020,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-19-2944","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22423346.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423352","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6511478.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423340","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423346","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423352.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423343","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423358.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423349","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423358","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6511478","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423349.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423343.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22423340.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}